Drugs for Gastrointestinal Diseases — MCQs

Drugs for Gastrointestinal Diseases Indian Medical PG Practice Questions and MCQs

Question 311: A patient with gastroesophageal reflux disease (GERD) is prescribed a proton pump inhibitor to reduce stomach acid production. Which enzyme is targeted by this drug?

A. Pepsin
B. Gastric lipase
C. H+/K+ ATPase (Correct Answer)
D. Carbonic anhydrase

Explanation: ***H+/K+ ATPase*** - Proton pump inhibitors (PPIs) directly target the **H+/K+ ATPase** (proton pump) in the parietal cells of the stomach [1], [2]. - This enzyme is responsible for the final common pathway of **acid secretion**, actively pumping hydrogen ions into the gastric lumen in exchange for potassium ions [1]. *Pepsin* - Pepsin is a **proteolytic enzyme** that becomes active in acidic environments but is not directly targeted by PPIs [1]. - While PPIs reduce the acidity required for optimal pepsin activity, they do not inhibit the enzyme itself. *Gastric lipase* - Gastric lipase is an enzyme involved in the digestion of **dietary fats** in the stomach. - It works optimally in an acidic environment, but PPIs do not directly inhibit its action. *Carbonic anhydrase* - **Carbonic anhydrase** is an enzyme that catalyzes the formation of carbonic acid, which then dissociates to provide hydrogen ions for the H+/K+ ATPase. - While it's involved in acid production, it's not the direct target of PPIs; instead, it's targeted by **carbonic anhydrase inhibitors** (e.g., acetazolamide), primarily used as diuretics or to treat glaucoma.

Question 312: Why is proton pump inhibitor therapy used in patients with gastroesophageal reflux disease (GERD)?

A. To increase gastric acid secretion
B. To reduce gastric acid production (Correct Answer)
C. To neutralize stomach acid
D. To enhance esophageal motility

Explanation: ***To reduce gastric acid production*** - **Proton pump inhibitors (PPIs)** irreversibly bind to and inhibit the **H+/K+-ATPase pump** on gastric parietal cells. - This action effectively **decreases the secretion of gastric acid**, which is the primary irritant in GERD. *To increase gastric acid secretion* - This is incorrect as increasing gastric acid secretion would worsen the symptoms of GERD by providing more acid to reflux into the esophagus. - PPIs are specifically designed to counteract excessive acid, not promote more of it. *To neutralize stomach acid* - **Antacids** (e.g., calcium carbonate, aluminum hydroxide) are medications that neutralize stomach acid, providing temporary relief. - PPIs do not neutralize existing acid but rather prevent its production. *To enhance esophageal motility* - Medications that enhance esophageal motility are known as **prokinetics** (e.g., metoclopramide) and are sometimes used in specific GERD cases. - PPIs do not directly affect esophageal motility but rather address the issue of stomach acid.

Question 313: A patient presents with a severe gastrointestinal ulcer due to nonsteroidal anti-inflammatory drugs (NSAIDs). Which agent would help reduce acidity and promote healing?

A. Aluminum hydroxide
B. Pantoprazole (Correct Answer)
C. Ranitidine
D. Sodium bicarbonate

Explanation: ***Pantoprazole*** - As a **proton pump inhibitor (PPI)**, pantoprazole potently and irreversibly blocks the H+/K+-ATPase pump in gastric parietal cells, significantly reducing **acid secretion** and promoting ulcer healing. - PPIs are the most effective class of drugs for treating and preventing **NSAID-induced ulcers** due to their superior acid-suppressing capabilities. - **First-line therapy** for severe NSAID-induced ulcers with the best evidence for healing and prevention. *Aluminum hydroxide* - This is an **antacid** that neutralizes existing stomach acid, providing temporary relief but not significantly promoting long-term ulcer healing. - Its effects are short-lived, and it does not inhibit further acid production, making it less effective for severe ulcers. *Ranitidine* - Ranitidine is an **H2-receptor antagonist** that blocks histamine's action on parietal cells, thereby reducing acid secretion. - While historically used for acid reduction, it is generally less potent and slower-acting than PPIs like pantoprazole for severe ulcers and does not irreversibly inhibit the proton pump. - **Note:** Ranitidine has been withdrawn from most markets worldwide (2019-2020) due to NDMA contamination concerns. Other H2 blockers like **famotidine** are now preferred alternatives. *Sodium bicarbonate* - This is a rapidly acting **antacid** that neutralizes stomach acid by forming carbon dioxide, leading to temporary relief. - Its use can cause **metabolic alkalosis** and is not suitable for sustained acid reduction or the healing of severe ulcers due to its short duration of action and potential side effects.

Question 314: Which serotonin 5-HT3 receptor antagonist is the most effective for preventing chemotherapy-induced nausea and vomiting?

A. Domperidone
B. Ondansetron (Correct Answer)
C. Metoclopramide
D. Meclizine

Explanation: ***Ondansetron*** - **Ondansetron** is a highly effective and commonly used **serotonin 5-HT3 receptor antagonist** specifically indicated for the prevention of **chemotherapy-induced nausea and vomiting (CINV)**. - It works by blocking serotonin receptors in the **chemoreceptor trigger zone (CTZ)** and on afferent vagal nerve fibers, thereby reducing the emetic response. *Domperidone* - **Domperidone** is a **dopamine receptor antagonist** that acts peripherally to increase gastrointestinal motility and is used for nausea, but it does not effectively target the 5-HT3 receptors involved in CINV. - It has a weaker antiemetic effect against CINV compared to 5-HT3 antagonists. *Metoclopramide* - **Metoclopramide** is a **dopamine receptor antagonist** with some 5-HT3 receptor antagonist properties at higher doses, but it is less selective and potent than ondansetron for 5-HT3 blockade. - It is often used for general nausea and vomiting but is not considered the most effective single agent for preventing severe CINV due to its broader receptor effects and potential for side effects like **extrapyramidal symptoms**. *Meclizine* - **Meclizine** is an **antihistamine** and **anticholinergic** agent primarily used for motion sickness and vertigo. - It does not act on serotonin 5-HT3 receptors and is therefore ineffective in preventing chemotherapy-induced nausea and vomiting.

Question 315: Which of the following is not a prokinetic agent?

A. 5HT4 agonist
B. Dopamine antagonist
C. Macrolides
D. Atropine (Correct Answer)

Explanation: **Atropine** - **Atropine** is an **anticholinergic agent** that blocks muscarinic acetylcholine receptors, leading to decreased gastrointestinal motility. - Prokinetic agents, in contrast, **enhance gastrointestinal motility**; therefore, atropine is not a prokinetic. *Dopamine antagonist* - **Dopamine D2 receptor antagonists** (e.g., metoclopramide, domperidone) are prokinetic agents because dopamine normally inhibits acetylcholine release in the gut. - By blocking dopamine's inhibitory action, these agents **promote acetylcholine release**, thereby increasing gastrointestinal motility. *5HT4 agonist* - **5-HT4 receptor agonists** (e.g., cisapride, prucalopride) stimulate acetylcholine release in the enteric nervous system. - This results in **enhanced gastrointestinal contractions** and accelerated transit, classifying them as prokinetic agents. *Macrolides* - Certain **macrolide antibiotics** (e.g., erythromycin) act as **motilin receptor agonists**. - Motilin is a hormone that **stimulates smooth muscle contraction** in the stomach and small intestine, making macrolides effective prokinetic agents.

Question 316: Which of the following is a Cl- channel activator related to gastrointestinal conditions?

A. Nefazodone
B. Valethamate
C. Lubiprostone (Correct Answer)
D. Varenicline

Explanation: **Lubiprostone** - Lubiprostone is a **prostanoid derivative** that specifically activates **chloride channels (ClC-2)** in the apical membrane of gastrointestinal epithelial cells [1]. - This activation leads to increased fluid secretion into the intestinal lumen, softening stool and promoting bowel movements, making it useful for treating **chronic idiopathic constipation (CIC)** and **irritable bowel syndrome with constipation (IBS-C)** [1]. *Nefazodone* - Nefazodone is an **antidepressant** that acts as a **serotonin 5-HT2 and alpha-1 adrenergic receptor antagonist**, and also inhibits serotonin and norepinephrine reuptake. - Its primary therapeutic use is in the treatment of **depression**, and it does not directly act as a chloride channel activator for gastrointestinal conditions. *Varenicline* - Varenicline is a **nicotinic acetylcholine receptor partial agonist** used primarily for **smoking cessation**. - It reduces cravings and withdrawal symptoms associated with nicotine addiction, with no direct action on chloride channels in the gastrointestinal tract. *Valethamate* - Valethamate is an **anticholinergic and antispasmodic agent** sometimes used to relieve smooth muscle spasms in the gastrointestinal or genitourinary tracts. - It works by blocking muscarinic receptors and does not directly activate chloride channels to promote fluid secretion.

Question 317: Which is the most potent H2 antagonist?

A. Ranitidine
B. Cimetidine
C. Famotidine (Correct Answer)
D. Nizatidine

Explanation: ***Famotidine*** - Famotidine is considered the **most potent H2 antagonist**, demonstrating a significantly **higher affinity** for the H2 receptor compared to other drugs in its class. - Its high potency allows for **effective acid suppression** at lower doses. *Ranitidine* - Ranitidine is a potent H2 antagonist, but it is **less potent than famotidine**. - It has been a widely used H2 blocker but is now less favored due to concerns about **NDMA contamination**. *Cimetidine* - Cimetidine was the **first H2 antagonist** introduced but is the **least potent** among the options listed. - It is associated with more drug interactions and side effects due to its inhibition of **cytochrome P450 enzymes**. *Nizatidine* - Nizatidine has a **similar potency to ranitidine**, making it less potent than famotidine. - It has a unique characteristic of being **primarily eliminated by the kidneys (excreted unchanged in urine)**.

Question 318: Erythromycin is used in the treatment of which GIT disorder?

A. Bacillary dysentery
B. Amoebic dysentery
C. Ulcerative colitis
D. Diabetic gastroparesis (Correct Answer)

Explanation: ***Diabetic gastroparesis*** - Erythromycin acts as a **motilin receptor agonist**, mimicking the effect of motilin, a hormone that stimulates **gastric motility**. - This prokinetic effect helps to improve **gastric emptying** in patients with diabetic gastroparesis, who often experience delayed emptying due to autonomic neuropathy. *Bacillary dysentery* - This condition is typically caused by bacterial infections like **Shigella**, requiring antibiotics such as **fluoroquinolones** or **azithromycin**. - Erythromycin is not a primary treatment for bacillary dysentery due to its limited efficacy against the common causative organisms and potential for increased resistance. *Amoebic dysentery* - Caused by the parasite **Entamoeba histolytica**, treatment involves **amoebicidal agents** like **metronidazole** followed by a luminal agent such as paromomycin. - Erythromycin has no significant activity against amoebae and is therefore ineffective in treating amoebic dysentery. *Ulcerative colitis* - This is an **inflammatory bowel disease** characterized by chronic inflammation of the colon, managed with **anti-inflammatory drugs** (e.g., mesalamine, corticosteroids) and **immunomodulators**. - Erythromycin has no role in directly treating the inflammation of ulcerative colitis; antibiotics may be used in specific cases of infectious complications, but not as primary therapy for the disease itself.

Question 319: The two molecules of Aminosalicylate coupled via azo bond form?

A. Mesalazine
B. Olsalazine (Correct Answer)
C. Balsalazine
D. Sulfasalazine

Explanation: ***Olsalazine*** - **Olsalazine** is formed by coupling two molecules of **5-aminosalicylate (5-ASA)** via an **azo bond**. - This design allows the drug to be cleaved by **bacterial azoreductases** in the colon, releasing active 5-ASA directly at the site of inflammation. *Mesalazine* - **Mesalazine** is the active compound **5-aminosalicylic acid (5-ASA)** itself, not a coupled dimer. - It is delivered to the colon via various formulations that protect it from absorption in the upper GI tract. *Balsalazine* - **Balsalazine** consists of **5-aminosalicylate (5-ASA)** linked to an inert carrier molecule (**4-aminobenzoyl-beta-alanine**) by an **azo bond**. - This linkage prevents early absorption and releases 5-ASA specifically in the colon. *Sulfasalazine* - **Sulfasalazine** is a prodrug composed of **sulfapyridine** and **5-aminosalicylate (5-ASA)** linked by an **azo bond**. - While it contains an azo bond, it involves 5-ASA and a sulfapyridine moiety, not two molecules of aminosalicylate.

Question 320: Racecadotril is primarily used for which type of diarrhea?

A. Chronic diarrhea
B. Acute secretory diarrhea (Correct Answer)
C. Chronic constipation
D. Diabetic gastroparesis

Explanation: ***Acute secretory diarrhea*** - **Racecadotril** is an **opioid-based antidiarrheal drug** that acts as an **enkephalinase inhibitor**. - It reduces the secretion of water and electrolytes into the intestine by inhibiting the degradation of **endogenous enkephalins**, which then bind to **delta-opioid receptors** on enterocytes, making it effective for secretory diarrhea. *Chronic diarrhea* - While racecadotril can reduce the symptoms of diarrhea, it is not the primary treatment for **chronic diarrhea**, which often requires identifying and treating the underlying cause. - Chronic diarrhea can be caused by various factors like **malabsorption**, **inflammatory bowel disease**, or **irritable bowel syndrome**, which racecadotril does not address directly. *Chronic constipation* - **Chronic constipation** involves infrequent or difficult bowel movements, which is the opposite of diarrhea. - Racecadotril works by reducing fluid secretion into the bowel and has no role in treating constipation; it would likely worsen it if used. *Diabetic gastroparesis* - **Diabetic gastroparesis** is a condition where stomach emptying is delayed, leading to symptoms like **nausea**, **vomiting**, and **early satiety**. - It is a disorder of motility, not primarily a secretory disorder of the small or large intestine, and is usually managed with **prokinetic agents** like metoclopramide or erythromycin.

Practice by Chapter

Acid-Peptic Disease Therapeutics

Practice Questions

Proton Pump Inhibitors

Practice Questions

H2 Receptor Antagonists

Practice Questions

Antacids and Mucosal Protectants

Practice Questions

Antiemetics

Practice Questions

Prokinetic Agents

Practice Questions

Laxatives and Purging Agents

Practice Questions

Antidiarrheal Drugs

Practice Questions

Drugs for Inflammatory Bowel Disease

Practice Questions

Pancreatic Enzyme Supplements

Practice Questions

Want unlimited practice?

Get full access to all questions, explanations, and performance tracking.

Start For Free